Semaglutide vs Metformin in Polycystic Ovary Syndrome (PCOS)

NCT05646199 · Not yet recruiting

Last updated 2026-05-28

This clinical trial compares the effects of semaglutide and metformin on weight loss in women with polycystic ovary syndrome (PCOS).

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase2, Phase3

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 60 people Planned (estimated).

Who can join Ages 18–45 · female only

Timeline Started 2025-03 · est. completion 2025-12

Where 1 site · United Kingdom

What this study is testing ClinicalTrials.gov NCT05646199 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to compare the effect of Semaglutide and metformin on weight loss in obese women with Polycystic Ovarian Syndrome (PCOS) over a 28-week treatment period. The main question it aims to answer is: • Which of the 2 drugs, metformin or Semaglutide causes more weight loss when used over a 28 week treatment period in obese women with PCOS? Participants will be divided into 2 groups by chance. In the first group, participants will be asked to take metformin orally. In the second group, participants will take Semaglutide by injection under the skin weekly. The maximum duration of participation for the patients in the trial is 32 weeks. Researchers will compare the weight reduction, quality of life and individuals' wellbeing between the two groups.

Treatments tested

Metformin Drug

Participants will receive metformin
Semaglutide Injectable Product Drug

Participants in this group will receive injectable Semaglutide

Main thing measured	Weight loss (kg)
Sponsor	University of Hull
Conditions studied	Polycystic Ovary Syndrome
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05646199 ↗